NYSE$PRGO

Perrigo Company · Q3 2020 earnings

Q3 2020 earnings · · Investor relations

Briefing

Perrigo's Q3 2020 performance was driven by Consumer Self-Care Americas, with consolidated net sales up 1.3% and adjusted EPS down 10.6% due to RX Albuterol recall.

Perrigo reported a 1.3% increase in consolidated net sales for Q3 2020, driven by growth in Consumer Self-Care Americas. However, adjusted EPS decreased by 10.6% due to a charge from the RX albuterol recall. The company reaffirmed its full-year adjusted EPS guidance.

  • Consolidated third quarter net sales increased by 1.3% to $1.2 billion.
  • Consumer Self-Care Americas achieved record third quarter net sales, up 7.3%.
  • Reported diluted net loss per share was $1.13, compared to EPS of $0.67 in the prior year.
  • Adjusted diluted EPS decreased 10.6% to $0.93, including a $0.14 charge from the RX albuterol recall.

Headline financials

Total Revenue

$1.21B

Previous: $1.19B+1.9%
EPS (adj)

$0.93

Previous: $1.04-10.6%
Adjusted Operating Income

$184M

No prior period
Reported Operating Margin

-7.9%

No prior period
Capital Expenditures

-$104M

Previous: -$90.3M-15.5%
Free Cash Flow

-$259M

Previous: $1.9M-13726.3%
Net Income

-$155M

Previous: $92.2M-267.7%
Operating Income

-$95.5M

Previous: $54.4M-275.6%
Gross Profit

$428M

Previous: $413M+3.7%
Cash & Equivalents

$849M

Previous: $399M+113.1%
Total Assets

$11.6B

Previous: $11.3B+2.3%
Stock-Based Comp

$14.2M

Previous: $12.9M+10.1%

Revenue & EPS history

Perrigo · Revenue · Quarterly

$1.21B

Q3 2020+1.9%vs Q3 2019
Beat estimate in 10 of 16 quarters(63%)
ActualEstimate

Revenue by segment

Perrigo · $1B total across 2 segments · Q3 2020

  • Consumer Self-Care Americas
    $664M
  • Consumer Self-Care International
    $339M

Forward guidance

The Company reaffirms its fiscal 2020 outlook with expected net sales growth of 6% to 7% with organic net sales growth of at least 3%. Adjusted diluted EPS is expected to be in the range of $3.95 to $4.15.

Tailwinds

  • Strong business fundamentals
  • Lower expected tax rate for the year

Headwinds

  • Incremental COVID-19 related costs ($0.12 - $0.15 per adjusted diluted share)
  • Impact from the RX albuterol sulfate recall ($0.14 per share)
  • Impact from the divested Rosemont Rx business ($0.06 per share)

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2020

Historical avgQ3 2020

-1.5%

Avg return

Earnings day

-2.1%

Avg return

5 days after

-3.4%

Avg return

30 days after

48%

30 / 63 earnings

Positive

+20.2%

Q4 2024

Best reaction

-25.2%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+5.3%-5.0%-7.0%
Q4 2025-1.5%-21.0%-33.9%
Q3 2025-25.2%-29.4%-33.4%
Q1 2025+7.2%+9.4%+6.0%
Q4 2024+20.2%+22.1%+16.3%
Q3 2024+6.2%+5.4%+10.7%
Q2 2024+1.8%-1.5%+3.3%
Q1 2024-6.9%-8.1%-19.2%
Q4 2023-17.9%-18.2%+0.1%
Q3 2023+2.0%-0.2%+7.3%
Q2 2023+5.8%+7.3%-8.4%
Q1 2023+1.3%-2.2%-6.5%
Q4 2022+3.9%+6.9%-3.2%
Q3 2022-18.3%-14.9%-18.2%
Q2 2022-1.9%-1.7%-9.3%
Q1 2022+9.1%+15.6%+19.7%
Q4 2021+6.4%+4.8%+8.2%
Q3 2021-8.7%-9.8%-23.0%
Q2 2021-16.0%-16.6%-11.1%
Q1 2021+6.1%+6.4%+13.3%
Q4 2020+4.3%+1.7%+0.3%
Q3 2020-0.3%+1.5%+9.9%
Q2 2020-8.5%-6.1%-7.7%
Q1 2020-3.0%-4.4%+0.8%
Q4 2019-16.4%-12.1%-24.0%
Q3 2019-8.1%-9.3%-3.4%
Q2 2019-7.1%-5.4%-1.1%
Q1 2019+7.5%+1.7%-10.1%
Q4 2018+0.8%+4.0%-0.3%
Q3 2018-14.7%-13.0%-20.2%
Q2 2018-10.7%-11.3%-3.3%
Q1 2018-4.9%+0.4%-5.2%
Q4 2017+1.9%-6.0%-5.6%
Q3 2017+8.0%+5.9%+5.4%
Q2 2017+18.3%+17.2%+24.7%
Q1 2017+4.1%+5.0%+8.5%
Q3 2016+6.9%+6.7%-1.2%
Q2 2016-9.8%-7.2%-6.7%
Q1 2016-4.7%
Q4 2015-10.9%
Q3 2015-1.3%
Q2 2015+1.7%
Q1 2015-1.7%
Q4 2014+6.7%
Q3 2014-11.3%
Q2 2014-4.9%
Q1 2014+10.7%
Q4 2013-5.1%
Q3 2013-0.5%
Q2 2013+5.2%
Q1 2013-8.8%
Q4 2012-8.3%
Q3 2012-4.5%
Q1 2012+1.8%
Q2 2012-0.1%
Q4 2011+1.3%
Q3 2011-7.6%
Q2 2011+2.7%
Q1 2011+1.7%
Q4 2010+0.6%
Q3 2010-0.1%
Q2 2010-2.9%
Q1 2010+0.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro